Kodiak Sciences closed at $99.87 on Oct 9, up 5.95% — matching its 52-week closing high. Volume of 1.7M shares was 0.46× its 20-day average (below normal).
Split-adjusted performance: +203.8% over one month, +131.7% over six months, +590.7% over one year.
Short interest was 9.4M shares at the Sep 30 settlement, down 12.1% from the prior report (31.7% of float, 1.8 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −10.7%, revenue growth +8.8%, net margin −231.7%, P/E 20.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KODKodiak Sciences | $99.87 | +5.95% | +131.7% | — | — | — | $6.28B | |
| IMVTImmunovant | $30.47 | +0.69% | +24.4% | — | — | — | $6.29B | Compare |
| IOVAIovance Biotherapeutics | $14.62 | +9.84% | +295.1% | +65.7% | −47.6% | — | $6.62B | Compare |
| CGONCG Oncology | $63.82 | +0.89% | −5.7% | — | −6832.8% | — | $5.66B | Compare |
| CRSPCRISPR Therapeutics AG | $53.39 | +5.85% | +4.2% | +1041.4% | −895.3% | — | $5.16B | Compare |
| SRRKScholar Rock Holding | $42.19 | −0.02% | −15.6% | — | — | — | $5.14B | Compare |
| ADPTAdaptive Biotechnologies | $26.49 | +1.53% | +107.1% | +21.5% | −55.6% | — | $4.23B | Compare |
| KYMRKymera Therapeutics | $112.40 | +2.84% | +32.2% | +466.4% | −94.2% | — | $9.35B | Compare |
| KRYSKrystal Biotech | $331.61 | +1.32% | +28.0% | +24.1% | 45.9% | 40.6 | $9.82B | Compare |
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
